↓ Skip to main content

Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis

Overview of attention for article published in Biomarker Research, February 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
Published in
Biomarker Research, February 2016
DOI 10.1186/s40364-016-0056-5
Pubmed ID
Authors

Abdulraheem Yacoub, Lindsey Prochaska, Yacoub, Abdulraheem, Prochaska, Lindsey

Abstract

Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms. Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life. Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 17%
Unknown 5 83%

Demographic breakdown

Readers by professional status Count As %
Professor 1 17%
Student > Master 1 17%
Student > Postgraduate 1 17%
Researcher 1 17%
Unspecified 1 17%
Other 0 0%
Unknown 1 17%
Readers by discipline Count As %
Medicine and Dentistry 3 50%
Agricultural and Biological Sciences 1 17%
Unspecified 1 17%
Unknown 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2016.
All research outputs
#5,738,224
of 10,281,628 outputs
Outputs from Biomarker Research
#30
of 86 outputs
Outputs of similar age
#168,397
of 343,960 outputs
Outputs of similar age from Biomarker Research
#3
of 11 outputs
Altmetric has tracked 10,281,628 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 86 research outputs from this source. They receive a mean Attention Score of 2.4. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,960 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.